SCHEMBL3841682

SCHEMBL3841682

N#Cc1cc(-c2ccncc2)c(-c2ccccc2F)nc1N

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 4/20 0.46
ADORA1 P30542 4/20 0.46
KDM4E B2RXH2 3/20 0.46
ALDH1A1 P00352 2/20 0.46
GAA P10253 2/20 0.46
HPGD P15428 2/20 0.46
GLA P06280 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
CHUK O15111 1/20 0.44
CYP11B1 P15538 1/20 0.42
CYP11B2 P19099 1/20 0.42
ADORA2B P29275 2/20 0.41
ADORA3 P0DMS8 1/20 0.41
CNR1 P21554 4/20 0.41
CNR2 P34972 3/20 0.41
NPC1 O15118 1/20 0.40
PKM P14618 1/20 0.40
RAB9A P51151 1/20 0.40
KMT2A Q03164 1/20 0.40
CSNK1D P48730 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6765596 0.82 ADORA1 (0.49) ADORA2AADORA1KDM4EALDH1A1GAA
SCHEMBL3841687 0.82 SQOR (0.47) ADORA2AADORA1KDM4EALDH1A1GAA
SCHEMBL25395577 0.79 KHK (0.49) ADORA2AADORA1KDM4EALDH1A1GAA
SCHEMBL25394068 0.79 MBNL1 (0.52) ADORA2AADORA1KDM4EALDH1A1GAA
SCHEMBL4905633 0.76 ALDH1A1 (0.51) ADORA2AADORA1KDM4EALDH1A1GAA
SCHEMBL3840501 0.76 PIK3R1 (0.49) ADORA2AADORA1KDM4EALDH1A1GAA
SCHEMBL22172395 0.75 MAP4K4 (0.54) KDM4EALDH1A1HPGDKMT2ALMNA
SCHEMBL29409515 0.74 PDE3B (0.51) KDM4EALDH1A1GAAHPGDKMT2A
SCHEMBL3482043 0.73 CNR1 (0.67) ADORA2AADORA1CNR1CNR2
SCHEMBL6250191 0.73 KDM4E (0.76) ADORA2AADORA1KDM4EALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1308441-B1 2-AMINOPYRIDINE COMPOUNDS AND USE THEREOF AS DRUGS EISAI R&D MAN CO LTD (JP) 2009-10-07 EP disclosed
US-6750232-B2 ADENOSINE ANTAGONIST; AN IMPORTANT REGULATORY FACTOR INVOLVED IN VARIOUS INTRACELLULAR METABOLISMS SUCH AS REGULATION OF ENERGY LEVELS EISAI CO., LTD. (JP) 2004-06-15 US disclosed
US-20040006082-A1 2-Aminopyridine compounds and use thereof as drugs EISAI R&D MANAGEMENT CO., LTD. (JP) 2004-01-08 US disclosed
EP-1308441-A1 2-AMINOPYRIDINE COMPOUNDS AND USE THEREOF AS DRUGS Eisai Co., Ltd. (JP) 2003-05-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040006082-A1 2-Aminopyridine compounds and use thereof as drugs ADORA1, ADORA2B, ADORA2A ADORA2A 3/4885ADORA1 1/4885KDM4E 768/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.